Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA.
Department of Pathology, School of Medicine, University of Michigan, Ann Arbor, MI, USA.
J Dent Res. 2023 Sep;102(10):1131-1140. doi: 10.1177/00220345231177996. Epub 2023 Jun 22.
Regeneration of alveolar bone is an essential step in restoring healthy function following tooth extraction. Growth of new bone in the healing extraction socket can be variable and often unpredictable when systemic comorbidities are present, leading to the need for additional therapeutic targets to accelerate the regenerative process. One such target is the TAM family (Tyro3, Axl, Mertk) of receptor tyrosine kinases. These proteins have been shown to help resolve inflammation and maintain bone homeostasis and thus may have therapeutic benefits in bone regeneration following extraction. Treatment of mice with a pan-TAM inhibitor (RXDX-106) led to accelerated alveolar bone fill following first molar extraction in a mouse model without changing immune infiltrate. Treatment of human alveolar bone mesenchymal stem cells with RXDX-106 upregulated Wnt signaling and primed the cells for osteogenic differentiation. Differentiation of human alveolar bone mesenchymal stem cells with osteogenic media and TAM-targeted inhibitor RXDX-106 (pan-TAM), ASP-2215 (Axl specific), or MRX-2843 (Mertk specific) showed enhanced mineralization with pan-TAM or Mertk-specific inhibitors and no change with Axl-specific inhibitor. First molar extractions in Mertk mice had increased alveolar bone regeneration in the extraction socket relative to wild type controls 7 d postextraction. Flow cytometry of 7-d extraction sockets showed no difference in immune cell numbers between Mertk and wild type mice. RNAseq of day 7 extraction sockets showed increased innate immune-related pathways and genes associated with bone differentiation in Mertk mice. Together, these results indicate that TAM receptor signaling, specifically through Mertk, can be targeted to enhance bone regeneration after injury.
牙槽骨再生是拔牙后恢复健康功能的关键步骤。当存在系统性合并症时,愈合拔牙窝中新骨的生长可能会有所不同,且通常不可预测,这导致需要额外的治疗靶点来加速再生过程。TAM 家族(Tyro3、Axl、Mertk)受体酪氨酸激酶就是这样的一个靶点。这些蛋白已被证明有助于解决炎症并维持骨内稳态,因此在拔牙后再生中可能具有治疗益处。在小鼠模型中,用 pan-TAM 抑制剂(RXDX-106)治疗可加速第一磨牙拔牙后的牙槽骨填充,而不会改变免疫浸润。用 RXDX-106 处理人牙槽骨间充质干细胞可上调 Wnt 信号通路,并使细胞为成骨分化做好准备。用成骨培养基和 TAM 靶向抑制剂 RXDX-106(pan-TAM)、ASP-2215(Axl 特异性)或 MRX-2843(Mertk 特异性)分化人牙槽骨间充质干细胞,显示出与 pan-TAM 或 Mertk 特异性抑制剂相比增强的矿化作用,而与 Axl 特异性抑制剂无变化。与野生型对照相比,Mertk 小鼠的第一磨牙拔牙后,拔牙窝中的牙槽骨再生增加。7 天拔牙窝的流式细胞术显示,Mertk 小鼠和野生型小鼠之间的免疫细胞数量没有差异。第 7 天拔牙窝的 RNAseq 显示,Mertk 小鼠中先天免疫相关途径和与骨分化相关的基因增加。总之,这些结果表明,TAM 受体信号,特别是通过 Mertk,可以作为靶点,增强损伤后的骨再生。